Promethera Biosciences appoints the new chairman of the board

10-Dec-2014 - Belgium

Promethera Biosciences announced that Dr John Tchelingerian has joined the company as chairman of the board. He will support Promethera to catalyze transformative transactions in the future. Dr John Tchelingerian joins the company at a time when Promethera is gearing up to launch a pivotal phase IIb/III trial in Europe and assess new, commercially attractive indications.

Dr John Tchelingerian is a serial entrepreneur and a private investor. His background includes strong scientific, business, managerial and deal making experience. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos. In the past ten years he has raised over $100 million (€ 81 million) for his entrepreneurial ventures from VCs and private equity sources in Europe, the US and Japan. He has also closed several biotech and pharma partnering deals. Under his leadership four drugs were developed from the research stage up to clinical phase IIb/III and a marketed drug, DaunoXome, was re-launched in a cancer orphan indication both in the USA and the EU, based on phase III clinical trials.

John co-founded a strategic advisory and corporate finance firm Silver Ocean Ventures in 2009; based in Paris. It primarily services the global life sciences industry regarding corporate finance, strategic business transactions and active board and leadership roles. Under his leadership Silver Ocean Ventures has closed several international capital raising and M&A transactions.

As a scientist, John has invented several patents in the field of cell therapy and drug delivery. He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris, France. He is fluent in five languages.

https://www.bionity.com/en/news/150843/promethera-biosciences-appoints-the-new-chairman-of-the-board.html